semaglutide우선순위 중간ICSR 검토기타
LITERATURE DETAIL · PMID 41125326
Hypoglycaemic coma induced by a falsified semaglutide product: a case report.
Hypoglycaemic coma induced by a falsified semaglutide product: a case report.
- 저자
- Giulia Antonacci, Erika Bortignon, Massimo Bolognesi, Salvatore Silvio Piano, Alessandro Cadore, Laura Camuffo
- 저널
- European journal of hospital pharmacy : science and practice
- 공개일
- 2026 Aug 19
- 연구 유형
- 기타
- DOI
- 10.1136/ejhpharm-2025-004656
문헌 요약
Semaglutide (Ozempic, Rybelsus, Wegovy) is a GLP-1 receptor agonist used for the treatment of type 2 diabetes and, more recently, weight management. Due to its efficacy in weight loss, semaglutide has gained worldwide popularity, particularly the branded version Ozempic, resulting in off-label use by people seeking rapid weight loss. The resulting high de…
PV 검토 포인트
개별 증례 가능성과 중대성, 예상성 및 중복 여부를 우선 검토합니다.